MeVis Medical Solutions AGFRA:M3V 66 EBITDA Margin % is 1.18% as of Mar. 2026, which is 97% below its 10-year median of 38.69. GuruFocus rates FRA:M3V with a GF Score™ of 66/100 and a GF Value™ of €22.52. The stock has 4 warning signs investors should review. Among 668 Healthcare Providers & Services companies, MeVis Medical Solutions AG ranks better than 54.04% on this metric.
MeVis Medical Solutions AG (FRA:M3V) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MeVis Medical Solutions AG EBITDA Margin % Related Terms
MeVis Medical Solutions AG EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M3V vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, MeVis Medical Solutions AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeVis Medical Solutions AG EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MeVis Medical Solutions AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeVis Medical Solutions AG (FRA:M3V) has a EBITDA Margin % of 1.18% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MeVis Medical Solutions AG and its competitors. This is 97% below median its historical median of 38.69. Over the past decade, MeVis Medical Solutions AG's EBITDA Margin % has ranged from 11.33 to 46.59. According to the industry distribution chart, MeVis Medical Solutions AG ranks #307 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 46%.
Is MeVis Medical Solutions AG's EBITDA Margin % too high?
MeVis Medical Solutions AG's current EBITDA Margin % of 1.18% is 97% below median its 10-year median of 38.69. Over the past 10 years, this metric has ranged from a low of 11.33 to a high of 46.59. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. MeVis Medical Solutions AG's value of 1.18% is 88.4% below this industry median. Based on the distribution chart, MeVis Medical Solutions AG ranks #307 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MeVis Medical Solutions AG ranks #307 out of 668 companies for EBITDA Margin %. This puts MeVis Medical Solutions AG in the upper half of its industry. The industry median EBITDA Margin % is 10.21. MeVis Medical Solutions AG's value of 1.18% is 88.4% below this benchmark. Historically, MeVis Medical Solutions AG's own EBITDA Margin % has ranged from 11.33 to 46.59 over the past decade. While the company's 10-year median is 38.69 vs. the industry median of 10.21, MeVis Medical Solutions AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeVis Medical Solutions AG's current EBITDA Margin % of 1.18% is 88.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MeVis Medical Solutions AG and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeVis Medical Solutions AG's current EBITDA Margin % is 1.18%, which is 97% below median its own 10-year median of 38.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
MeVis Medical Solutions AG (FRA:M3V) has a current EBITDA Margin % of 1.18%. The stock's GF Value™ is €22.52, compared to a current price of €23.20 — trading 3% above its estimated fair value. The current EBITDA Margin % is 1.18%, which is 97% below median its 10-year median of 38.69 and 88.4% below the Healthcare Providers & Services industry median of 10.21. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current EBITDA Margin % is 1.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?
Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued.
The current stock price of €23.20 is trading 3% above its estimated GF Value™ of €22.52.
Key valuation signals for FRA:M3V:
EBITDA Margin %: 1.18% (97% below median its 10-year median of 38.69)
GF Value™: €22.52 vs. price of €23.20 (3% above fair value)
Industry Position: 88.4% below the Healthcare Providers & Services median (#307 of 668)
No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
66GF Score
Get the complete analysis for FRA:M3V
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M3V has been successfully added to your 
